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Vascular development begins with the formation of a primary vascular plexus that is rapidly remodeled by angiogenesis into the
interconnected branched patterns characteristic of mature vasculature. Several receptor tyrosine kinases and their ligands have been
implicated to control early development of the vascular system. These include the vascular endothelial growth factor receptors (VEGFR-1
and VEGFR-2) that bind VEGF, the Tie-1 and Tie-2 receptors that bind the angiopoietins, and the EphB4 receptor that binds the membrane-
anchored ligand ephrin-B2. Targeted mutations in the mouse germline have revealed essential functions for these molecules in vascular
development. In particular, protein-null mutations that delete either EphB4 or ephrin-B2 from the mouse have been shown to result in early
embryonic lethality due to failed angiogenic remodeling. The venous expression of EphB4 and arterial expression of ephrin-B2 has lead to
the speculation that the interaction of these two molecules leads to bidirectional signaling into both the receptor-expressing cell and the
ligand-expressing cell, and that both forward and reverse signals are required for proper development of blood vessels in the embryo. Indeed,
targeted removal of the ephrin-B2 carboxy-terminal cytoplasmic tail by another group was shown to perturb vascular development and result
in the same early embryonic lethality as the null mutation, leading the authors to propose that ephrin-B2 reverse signaling directs early
angiogenic remodeling of the primary vascular plexus [Cell 104 (2001) 57]. However, we show here that the carboxy-terminal cytoplasmic
domain of ephrin-B2, and hence reverse signaling, is not required during early vascular development, but it is necessary for neonatal survival
and functions later in cardiovascular development in the maturation of cardiac valve leaflets. We further show that ephrin-B2 reverse
signaling is required for the pathfinding of axons that form the posterior tract of the anterior commissure. Our results thus indicate that ephrin-
B2 functions in the early embryo as a typical instructive ligand to stimulate EphB4 receptor forward signaling during angiogenic remodeling
and that later in embryonic development ephrin-B2 functions as a receptor to transduce reverse signals involved in cardiac valve maturation
and axon pathfinding.
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The large family of Eph receptor tyrosine kinases and
their membrane-anchored ephrin ligands have been impli-
cated to control a diverse array of cell movements by
regulating repulsion and adhesion events such as those
involved in axon guidance and cell migration (Cowan and
Henkemeyer, 2002; Frisen et al., 1999; Gale and Yanco-
poulos, 1999; Holmberg and Frisen, 2002; Kullander and
Klein, 2002; Wilkinson, 2001). They accomplish this by
transducing bidirectional tyrosine kinase-mediated signals
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and the ligand-expressing cell in what has been termed
forward and reverse signaling, respectively (Cowan and
Henkemeyer, 2002). Thus, Eph molecules are thought to
act as both receptors to transduce cell autonomous forward
signals into their cell and as ligands to stimulate noncell
autonomous reverse signaling into adjacent ephrin-express-
ing cells. Likewise, the ephrins are thought to function as
ligands to stimulate noncell autonomous forward signaling
in adjacent Eph-expressing cells and as receptors to trans-
duce cell autonomous reverse signals into their cell.
Development of the vascular system begins with the
formation of a primary vascular plexus that is rapidly
remodeled by angiogenesis into the interconnected branched
patterns characteristic of mature blood vessels (Risau, 1997;
Risau and Flamme, 1995). A number of different receptor
tyrosine kinase families and their ligands have been impli-
cated to play important roles in the early development of
blood vessels and formation of the cardiovascular system
(Adams and Klein, 2000; Flamme et al., 1997; Gale and
Yancopoulos, 1999; Merenmies et al., 1997; Risau, 1997;
Tallquist et al., 1999; Yancopoulos et al., 2000). Two key
players are EphB4, which is specifically expressed in veins,
and ephrin-B2, which is specifically expressed in arteries
and the perivascular mesenchyme (Adams et al., 1999; Gale
et al., 2001; Gerety et al., 1999; Wang et al., 1998). Prior
studies determined that targeted, protein-null alleles of
murine EphB4 or ephrin-B2 lead to early embryonic lethal-
ity due to a complete arrest of angiogenesis and failed
cardiovascular development (Adams et al., 1999; Gerety et
al., 1999; Wang et al., 1998). Additional genetic studies in
mice determined that the arterial expression of ephrin-B2 is
essential for its function in angiogenesis (Gerety and Ander-
son, 2002).
Given the restricted expression of EphB4 to veins and
ephrin-B2 to arteries, it has been tempting to speculate that
the roles for these two receptor-ligand pairs in the cardio-
vascular system is to regulate blood vessel development by
transducing bidirectional tyrosine kinase signals into both
the veins (forward signals) and the arteries (reverse signals)
as these two cell types come in contact with each other
(Adams, 2002; Adams, 2003; Adams and Klein, 2000;
Augustin and Reiss, 2003; Cheng et al., 2002; Gale and
Yancopoulos, 1999; Yancopoulos et al., 2000). Consistent
with the idea that ephrin-B2 can function as a receptor to
transduce important reverse signals into arteries, it was
reported that truncation of the majority of the ephrin-B2
carboxy-terminal cytoplasmic tail results in the same em-
bryonic lethality as the null allele, leading the authors to
conclude that reverse signals stemming from this ephrin are
important for early cardiovascular development (Adams et
al., 2001). We have also generated two targeted mutations in
mice that delete the cytoplasmic domain of ephrin-B2
(Dravis et al., 2004). Both mutations delete the same
cytoplasmic residues as the Adams et al. (2001) study
(amino acids 264–336), with one allele conjugating beta-galactosidase (hgal) to the truncated tail (the ephrin-B2–
hgal fusion protein) and the other allele producing an
unconjugated truncation (the ephrin-B2-DC protein) similar
to the previous study, which added a short HA epitope tag to
the truncated ephrin-B2 molecule (ephrin-B2-DC-HA). Al-
though we find that our ephrin-B2-DC protein results in the
same early embryonic lethality with severe defects in
vascular development as Adams et al. (2001) found for
their ephrin-B2-DC-HA protein, we find that the ephrin-
B2–hgal fusion protein allows for normal angiogenesis, full
embryonic development, and the birth of live pups. The
ability of the ephrin-B2–hgal fusion protein to produce
fully developed embryos that are live born demonstrates that
the carboxy-terminal cytoplasmic domain of ephrin-B2 is
not essential for vascular development and indicates that
reverse signaling is dispensable for angiogenesis. Consistent
with this functional data, we find that our truncated ephrin-
B2-DC protein, and likely the ephrin-B2-DC-HA protein
reported by Adams et al. (2001), does not traffic to the
plasma membrane but rather becomes trapped in the trans-
Golgi network and thus acts essentially like a protein-null.
As the ephrin-B2–hgal fusion protein does traffic to the cell
surface, it can function as a proper ligand to bind EphB
receptors and stimulate forward signaling.Methods
Mice
Mice carrying mutations in the ephrin-B2 gene are
described in the accompanying article (Dravis et al.,
2004). X-gal staining of ephrin-B2lacZ animals to detect
expression of the ephrin-B2–hgal fusion protein is de-
scribed elsewhere (Henkemeyer et al., 1996).
Flow cytometry
Mouse embryo fibroblasts were isolated at E9 from
ephrin-B2+/+, ephrin-B2lacZ/+, ephrin-B2lacZ/lacZ, ephrin-
B2T/+, and ephrin-B2T/T animals using 0.05% trypsin and
1 mg/ml collagenase at 37jC for 2–5 min with titration.
Cell suspensions were washed and expanded in vitro in
DMEM supplemented with 15% fetal bovine serum, peni-
cillin or streptomycin, L-glutamine, and nonessential amino
acids. Following expansion, fibroblasts were isolated with
0.5 mM EDTA/0.5 mM EGTA, washed with staining buffer
(PBS + 2% BSA + 0.2% sodium azide), and incubated for 1
h at 4jC with rabbit anti-ephrin-B2 extracellular domain
antibodies (P-20 or H-83, Santa Cruz Biotechnology, Santa
Cruz, CA). Cells were then washed with staining buffer and
incubated with biotinylated goat anti-rabbit IgG(H+L) sec-
ondary antibody (Caltag, Burlingame, CA) for 45 min at
4jC. Finally, cells were washed with staining buffer and
incubated for 30 min with streptavidin-PE (Caltag). Control
stains were performed always and included secondary
Table 1
Ephrin-B2lacZ/lacZ homozygotes survive embryonic development
Cross Stage +/+ +/ /
ephrin-B2T/+  ephrin-B2T/+ E9 10 20 8a
E10 25 46 21a
ephrin-B2lacZ/+  ephrin-B2lacZ/+ E9 3 9 3
E10 23 30 11
E11 30 56 13
E12 17 43 13
E13–E18 105 178 43
b
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antibody for ephrin-B2. Cell surface expression of ephrin-
B2 was analyzed on a FACScan (BD Biosciences, San Jose,
CA). Forward and side scatter gates were adjusted to include
only nucleated cells. Postexperiment analysis was per-
formed using CellQuest Pro software (BD Biosciences).
Immunofluorescence
Mouse embryo yolk sacs isolated at E10 from ephrin-
B2+/+, ephrin-B2lacZ/+, ephrin-B2lacZ/lacZ, ephrin-B2T/+, and
ephrin-B2T/T animals were fixed in 4% paraformaldehyde
in PBS for 30 min at 4jC, washed in PBS, and then
blocked in PBS containing 0.1% Tween-20, 2% BSA,
and 1% normal goat serum. Yolk sacs were incubated with
goat anti-mouse ephrin-B2 extracellular domain antibodies
(AF496, R&D Systems, Minneapolis, MN), rat anti-mouse
PECAM-1 (CD31) monoclonal antibodies (clone
MEC13.3, BD Biosciences), and either mouse anti-Syn-
taxin 6 monoclonal antibodies (clone 3D10/VAM-SV025,
StressGen Biotechnologies, Victoria, BC, Canada), mouse
anti-Membrin monoclonal antibodies (clone 4HAD6/VAM-
PT046, StressGen Biotechnologies), or rabbit anti-Calnexin
polyclonal antibodies (SPA-860, StressGen Biotechnolo-
gies). Yolk sacs were then washed extensively in PBS,
incubated with appropriate fluorescent-conjugated second-
ary antibodies (Jackson ImmunoResearch, West Grove,
PA), washed, mounted, and images were acquired with a
confocal microscope (Zeiss LSM 510) and processed with
Adobe Photoshop.
Horizontal cryosections bisecting the anterior commis-
sure of ephrin-B2+/+ wild-type and ephrin-B2lacZ/lacZ mutant
brains collected at E18 were fixed in 4% paraformaldehyde
in PBS for 30 min at 4jC, washed in PBS, and then blocked
in PBS containing 0.1% Tween-20, 2% BSA, and 1%
normal goat serum. Brain sections were incubated with
Tag1 and L1 antibodies (Developmental Studies Hybridoma
Bank, University of Iowa), washed, incubated with appro-
priate fluorescent-conjugated secondary antibodies (Jackson
ImmunoResearch), washed, mounted, and images were
acquired with a confocal microscope (Zeiss LSM 510) and
processed with Adobe Photoshop.
neonate 11 12 5
adult 153 170 0
Fertile, heterozygous males and females of the indicated genotypes were
mated and resulting offspring were scored at the various embryonic,
neonatal, and adult stages. Note that only approximately 50% of the
expected number of ephrin-B2lacZ/lacZ homozygous embryos were
recovered when compared to the numbers of ephrin-B2lacZ/+ and
ephrin-B2+/+ embryos obtained. This is because approximately 50% of
the ephrin-B2lacZ/lacZ homozygotes exhibit peri-implantation lethality that
may be due to defects in placentation.
a All ephrin-B2T/T homozygotes collected were visibly abnormal, appearing
growth-retarded and necrotic. All showed obvious defects in both
embryonic (cardiovascular) and extraembryonic (yolk sac) blood vessels.
No viable ephrin-B2T/T homozygotes were present at later stages of
development.
b The ephrin-B2lacZ/lacZ homozygotes were born alive and started breathing;
however, they expired within 24 h.Results and discussion
Ephrin-B2lacZ/lacZ homozygotes survive embryonic
development and are live born
Homologous recombination in murine embryonic stem
cells was used to target the ephrin-B2 gene (see Dravis et
al., 2004). The ephrin-B2lacZ allele replaces the sequence
encoding most of the cytoplasmic domain (amino acids
264–336) with an in-frame lacZ cassette, leading to
expression of an ephrin-B2-hgal fusion protein. By specif-
ically deleting only the cytoplasmic domain, the ephrin-B2-hgal protein will traffic to the membrane (see below) and
interact with Eph receptors on adjacent cells to activate
forward signaling, but it will not be able to interact with
intracellular SH2 and PDZ domain-containing proteins, and
is therefore unable to participate in reverse signaling. The
second mutation, termed ephrin-B2T, produces a protein
(termed ephrin-B2-DC) that truncates the cytoplasmic do-
main of ephrin-B2 at the same residue 264 as the ephrin-
B2lacZ allele; however, it does not have h-gal attached to
the tail.
When ephrin-B2T/+ heterozygous mice were inter-
crossed, no ephrin-B2T/T homozygous animals were ob-
served at birth. Further analysis of the lethal phenotype at
early gestation stages (E9 and E10 days development)
revealed that ephrin-B2T/T homozygotes exhibited a failure
in cardiovascular development (Table 1). Mutant embryos
were smaller, had enlarged pericardia, and displayed abnor-
mal heart and vascular structures, consistent with disrupted
angiogenic remodeling of the primary capillary plexus (Fig.
1A). Similar remodeling defects were also observed in the
blood vessels within the yolk sacs of the ephrin-B2T/T
homozygotes (Fig. 2G). These results are identical to what
has been reported for ephrin-B2 protein-null mice (Adams et
al., 1999; Wang et al., 1998) and animals harboring the
truncation mutation in ephrin-B2 described by Adams et al.
(2001).
However, quite surprisingly, when ephrin-B2lacZ/+ het-
erozygous animals were intercrossed, live ephrin-B2lacZ/lacZ
homozygous mutant newborns were observed, although
they died within the first day (Table 1). Analysis throughout
gestation (E9 until birth) revealed that ephrin-B2lacZ/lacZ
Fig. 1. The ephrin-B2 carboxy-terminus is not required for embryonic development. (A) Whole-mount embryos of the indicated genotypes collected at E10
show that ephrin-B2T/T homozygotes expressing a truncated, unconjugated ephrin-B2 display delayed development and embryonic lethality due to defective
cardiovascular development. In contrast, ephrin-B2lacZ/lacZ homozygotes that express a similarly truncated ephrin-B2–hgal fusion protein appear normal. (B)
Whole-mount embryos stained at E12 with X-gal to reveal expression of the ephrin-B2-hgal fusion protein. The ephrin-B2lacZ/lacZ homozygote appears normal
and, as expected, stains twice as strongly as the ephrin-B2lacZ/+ heterozygote. (C) The ephrin-B2lacZ/lacZ homozygotes survive embryonic development and are
live born.
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from wild-type littermates (Fig. 1). Importantly, these ani-
mals exhibited none of the early vascular defects associated
with the truncated ephrin-B2T allele (Fig. 2). The observa-
tion of live-born ephrin-B2lacZ/lacZ mutants indicates the
cytoplasmic domain of ephrin-B2 is not required for early
vascular development or embryonic survival as previously
proposed (Adams et al., 2001), and suggests the truncated
protein produced by the ephrin-B2T allele is nonfunctional.
The ephrin-B2-bgal fusion protein is localized to the plasma
membrane but the ephrin-B2-DC protein is trapped in the
trans-Golgi network
To gain insight into the observed phenotypic differences
between the ephrin-B2T and ephrin-B2lacZ alleles, we per-
formed a series of experiments to characterize the gene
products of the two mutant alleles. We analyzed the cell-surface expression of the various ephrin-B2 proteins on
murine embryo fibroblasts derived from E9 wild-type,
ephrin-B2lacZ, and ephrin-B2T heterozygous and homozy-
gous animals by fluorescence-activated cell sorting using
antibodies raised against the extracellular region of ephrin-
B2 (Fig. 3A). This analysis revealed that 9.5% of the wild-
type cells were positive for cell-surface ephrin-B2. Similar-
ly, cell-surface ephrin-B2 protein was observed in 14.3% of
the ephrin-B2lacZ/+ heterozygous cells, 16.6% of the ephrin-
B2lacZ/lacZ homozygous cells, and 12.5% of the ephrin-B2T/+
cells. In stark contrast, the cells from ephrin-B2T/T homo-
zygous embryos showed no detectable cell-surface ephrin-
B2 protein. These results indicate that the truncated ephrin-
B2-DC protein does not become properly localized to the
cell surface. The higher percentage of the ephrin-B2-hgal
fusion protein on the cell surface may be due to an increase
in protein stability conferred by the h-gal moiety and/or a
reduction in protein turnover.
Fig. 2. The ephrin-B2 carboxy-terminus is not required for blood vessel development. (A–F) Whole mounts of ephrin-B2lacZ/lacZ homozygotes collected at E11
(A to E) or E12 (F) and stained with X-gal reveals strong expression of the ephrin-B2-hgal fusion protein in arteries. Note normal branching of blood vessels
forming the carotid artery in the brain (A), blood vessels in the limb bud (B), in the dorsal aorta and its intersegmental branches (C and D), and in the yolk sac
(E and F). (G) Yolk sacs collected from the indicated genotypes at E10 were stained with anti-PECAM antibodies to reveal blood vessel architecture. The
ephrin-B2T/T homozygotes show an abnormal primitive honeycombed organization of similar-sized vessels. In contrast, blood vessels in the ephrin-B2lacZ/lacZ
mutant yolk sac appear normal and consist of both large and small vessels.
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analysis of E10 yolk sacs from wild-type, ephrin-B2lacZ,
and ephrin-B2T embryos using antibodies raised against the
extracellular region of ephrin-B2. Expression of each gene
product was detected in PECAM positive yolk sac endo-
thelial cells (Figs. 3B–D). Wild-type ephrin-B2 protein
was observed in small discrete spots on the plasma mem-
brane of these cells (Fig. 3B). Similarly, the ephrin-B2-hgal
fusion protein was also observed in distinct spots on the
cell surface (Fig. 3C). Intriguingly, the ephrin-B2-DCprotein did not cluster to spots on the plasma membrane,
but rather appeared to reside in irregularly shaped intracel-
lular structures (Fig. 3D). Biochemical analysis of the
previously reported truncated ephrin-B2-DC-HA protein
showed that this molecule could be precipitated by
wheat-germ agglutinin due to posttranslational covalent
addition of carbohydrate moieties to the extracellular por-
tion of the protein (Adams et al., 2001). As carbohydrates
are added to proteins in the endoplasmic reticulum (ER)
and Golgi apparatus of cells, it seemed likely that the
Fig. 3. The truncated ephrin-B2-DC protein is not localized to the plasma membrane. (A) Flow cytometry was used to measure the surface expression of ephrin-
B2 protein in embryonic fibroblasts obtained from the indicated genotypes. Shown is a representative example of experiments using four different cell lines for
each genotype class and two different antibodies directed against the ephrin-B2 extracellular domain. Note that the ephrin-B2T/T homozygote cells show only
background levels of cell-surface ephrin-B2 (compare to the unstained control where the primary antibody was omitted from wild-type cells). All other
genotypes showed strong expression of ephrin-B2 protein on the cell surface, including the ephrin-B2lacZ/lacZ homozygotes. (B–E) An antibody raised against
the extracellular domain of ephrin-B2 was used along with anti-PECAM-1 (blood vessels) and anti-Syn6 (trans-Golgi network) antibodies to triple label yolk
sacs from ephrin-B2+/+ wild-type (B), ephrin-B2lacZ/lacZ homozygote (C), and ephrin-B2T/T homozygote (D) embryos collected at E10. The ephrin-B2lacZ-
encoded ephrin-B2-hgal fusion protein shows normal localization to distinct spots on the surface of endothelial cells just like what is observed for the wild-type
protein, while the truncated, unconjugated ephrin-B2-DC protein encoded by the ephrin-B2T allele is trapped in the trans-Golgi network. Note in the merged
images the complete overlap of the ephrin-B2 staining (arrows) with the Syn6 marker for the trans-Golgi network (arrowheads) in the ephrin-B2T/T
homozygotes. (E) Summary of results.
C.A. Cowan et al. / Developmental Biology 271 (2004) 263–271268truncated ephrin-B2-DC protein might be aberrantly mis-
localized to one of these subcellular compartments. We
therefore performed triple immunofluorescent labeling of
E10 wild-type, ephrin-B2lacZ, and ephrin-B2T yolk sacs
with antibodies directed against ephrin-B2, PECAM, and
either an ER resident protein (Calnexin), a cis-Golgi
marker (Membrin), or a marker of the trans-Golgi network
(Syntaxin 6). This analysis revealed the truncated ephrin-
B2-DC protein specifically colocalized with the trans-Golginetwork marker Syntaxin 6 (Fig. 3D). The wild-type
ephrin-B2 protein and the ephrin-B2-hgal fusion protein
did not colocalize with any of these ER and Golgi markers,
indicating proper transport of these molecules through the
intracellular compartments and a normal cell-surface posi-
tioning (Figs. 3B, C). These data show that the ephrin-B2-
DC protein is inappropriately trapped within the trans-
Golgi network and is not properly localized to the surface
of the cell.
Fig. 4. The ephrin-B2 cytoplasmic domain is required for normal cardiac
valve development. (A) Hematoxylin–eosin stained transverse sections of
wild-type (left panels) and ephrin-B2lacZ/lacZ homozygote (right panels)
hearts collected at birth. The low magnification images (upper panels)
indicate an overall normal chamber formation and vascular connections in
the mutants. However, high magnification images of the valve regions
(lower panels) reveal enlarged hyperplastic aortic and pulmonary valves
(AoV and PV) in the mutants (asterisks). The mitral valve (MV) leaflets
were slightly thicker in the mutants. (B) X-gal staining of ephrin-B2lacZ/+
heterozygotes collected at E14 shows strong expression of ephrin-B2-hgal
in the epithelial cell layer of the developing valve leaflets (arrows).
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allele functionally mimics a protein null as the truncated
ephrin-B2-DC protein is both incapable of transducing
reverse signals and unable to bind Eph receptors and
activate forward signaling due to its abnormal intracellular
location in the trans-Golgi network (Fig. 3E). Thus, the
ephrin-B2lacZ allele provides a better genetic model to
understand the biological functions of ephrin-B2 reverse
signaling as this protein is properly localized to the cell
surface and is therefore able to act as a ligand to interact
with Eph receptors on adjacent cells and activate forward
signaling while the replacement of the cytoplasmic tail by
h-gal selectively disrupts reverse signals (Fig. 3E). Nota-
bly, the absence of early lethality associated with defects in
vascular development in ephrin-B2lacZ/lacZ homozygotes
indicates that reverse signaling by ephrin-B2 is not re-
quired for morphogenesis of the embryonic vasculature.
Ephrin-B2lacZ/lacZ homozygotes exhibit thickened cardiac
valves
Our initial observation that ephrin-B2lacZ/lacZ homozy-
gotes died within the first day after birth indicated that cell
autonomous ephrin-B2 mediated reverse signaling, while
not required for embryonic development, is required for
neonatal survival. To investigate the consequences of dis-
rupting ephrin-B2 reverse signaling, we performed a de-
tailed histological examination of ephrin-B2lacZ/lacZ
homozygotes at late gestational stages. Transverse sections
of the heart at E18 and P0 revealed normal chamber
formation and vascular connections in the ephrin-B2lacZ/lacZ
homozygotes. However, closer inspection revealed a marked
thickening of the aortic and pulmonary valves in all mutant
animals examined (n = 10; Fig. 4A). Cell counting revealed
that there were approximately twice as many mesenchymal
cells in the mutant aortic and pulmonary valves compared to
the wild type. Furthermore, the mitral valve leaflets were
slightly hyperplastic with approximately 30% more mesen-
chymal cells, while the tricuspid valve exhibited no signif-
icant change in leaflet size. X-gal staining of ephrin-B2
lacZ/+
heterozygotes at E14 showed strong expression of ephrin-
B2-hgal in the epithelia of the valve leaflets in the devel-
oping heart (Fig. 4B). This endocardial epithelial layer
receives signals from TGFh family members from the
myocardium that instruct them to transform into mesenchy-
mal cells, which in turn then detach and migrate into the
underlying extracellular matrix to form the valve tissue
(Barnett and Desgrosellier, 2003; Eisenberg and Markwald,
1995; Schroeder et al., 2003). Our data thus indicate ephrin-
B2 functions in a cell autonomous fashion in the epithelial
cells of the developing valve leaflets to transduce reverse
signals that help regulate the growth, transformation, or
migration of cells that form valve tissue. It is interesting to
note that possible roles for ephrin-B2 reverse signaling in
mesenchymal-to-epithelial transitions (e.g., somite forma-
tion) have recently been appreciated (Barrios et al., 2003).Disrupted pathfinding of anterior commissure axons in
ephrin-B2lacZ/lacZ homozygotes
We also asked whether ephrin-B2 reverse signaling was
required for the pathfinding of axons that form the posterior
tract of the anterior commissure (acP), a major forebrain
commissure that connects the two temporal lobes of the
cortex. We previously determined that the EphB2 receptor
C.A. Cowan et al. / Developmental Biology 271 (2004) 263–271270tyrosine kinase acted in a noncell autonomous manner as a
ligand to direct the pathfinding of acP axons across the
midline of the brain (Henkemeyer et al., 1996). As ephrin-B
molecules were found to be expressed in the axons formingthe acP tract, the data led to the hypothesis that the ephrins
can also function as receptors to transduce cell autonomous
reverse signals that help guide axons across the midline of
the brain to their final destination (Henkemeyer et al., 1996).
In an effort to confirm this hypothesis, we investigated the
pathfinding of acP axons in ephrin-B2lacZ animals. Coronal
cryosections of ephrin-B2lacZ/+ heterozygous brains dissect-
ed at E16 and stained with X-gal showed a normal anterior
commissure that strongly expressed the ephrin-B2-hgal
fusion protein in axons of the acP tract (Fig. 5A). Horizontal
cryosections of the forebrain of ephrin-B2lacZ/+ heterozy-
gous confirmed that ephrin-B2 was expressed in axons of
the acP as well as axon fibers of the anterior tract of this
commissure (acA) (Fig. 5B). Further histological examina-
tion showed that the formation of the acP tract was severely
compromised in all ephrin-B2lacZ/lacZ homozygotes ana-
lyzed (n > 15) as illustrated by the failure of these axons
to extend across the midline of the brain (Figs. 5B–D). The
observed axon pathfinding defects in ephrin-B2lacZ/lacZ
homozygotes strongly suggest that ephrin-B2 is functioning
as a receptor in the acP axons to transduce reverse signals
that are required for the guidance of these nerve fibers
across the midline of the brain.Conclusion
Our results indicate that ephrin-B2 reverse signals are not
required for early cardiovascular development as previously
described (Adams et al., 2001), but that this protein must be
present at the cell surface to act as a ligand for Eph receptors
to properly remodel the primary capillary plexus. When
these data are combined with the findings that mice lacking
the EphB4 receptor exhibit embryonic lethality due to a
similar failure in cardiovascular development (Gerety et al.,Fig. 5. The ephrin-B2 cytoplasmic domain is required for pathfinding of
anterior commissure axons. (A) Low (left) and high (right) magnification of a
coronal section from an E16 day ephrin-B2lacZ/+ heterozygote forebrain
stained with X-gal. Note strong expression of ephrin-B2-hgal in the cortex
and in the axons of the posterior tract of the anterior commissure (acP). The
anterior tract (acA) is not visible in this section. Note that blood vessels in the
brain also stain strongly for ephrin-B2 (arrows). (B) High magnification of
horizontal sections from E16 day forebrains stained with X-gal. The staining
for ephrin-B2-hgal in an ephrin-B2lacZ/+ heterozygote brain is localized to
axons that form both the acA and acP tracts. In ephrin-B2lacZ/lacZ homozygote
brains, the acP tract is much reduced, while the acA tract appears normal.
Also, note that the acA tract stains approximately twice as much for the
ephrin-B2-hgal fusion protein in the homozygotes, indicating the increased
gene dosage of the lacZ allele. (C and D) The upper panels show dark field
images of serial horizontal sections (starting from the ventral floor of the left
forebrain) of an ephrin-B2+/+ wild-type (C) and ephrin-B2lacZ/lacZ homozy-
gote (D) to reveal the acA and acP tracts of the anterior commissure. The acP
axons are severely reduced in the mutant. The bottom panels show confocal
images of horizontal sections of ephrin-B2+/+ wild-type (C) and ephrin-
B2lacZ/lacZ homozygote (D) forebrains double labeled with L1 antibodies to
detect major axon bundles including the acA and acP tracts (green signal) and
with TAG-1 to detect the acA tract (red signal). The acP tract is greatly
reduced in the mutants (arrows).
C.A. Cowan et al. / Developmental Biology 271 (2004) 263–271 2711999), it becomes likely that forward signaling from EphB4
is responsible for directing early remodeling of the capillary
plexus. While our results indicate ephrin-B2 is acting as a
typical ligand to stimulate EphB4 forward signaling in
developing blood vessels, ephrin-B2 does appear to act as
a receptor to transduce reverse signals later in cardiovascu-
lar development during the formation of cardiac valve
leaflets. Indeed, the massive hyperplastic thickening of the
aortic and pulmonary valves likely leads to the neonatal
lethality associated with the ephrin-B2lacZ/lacZ homozygotes.
Our data also indicate ephrin-B2 reverse signals are required
for the pathfinding of axons that form a major forebrain
commissure, the posterior tract of the anterior commissure.
This result validates the original hypothesis that ephrin
ligands are capable of acting like receptors to transduce
reverse signals into their own cell as first proposed follow-
ing observations of a similar defect in the anterior commis-
sure in EphB2null animals (Henkemeyer et al., 1996). Thus,
our ephrin-B2lacZ mice provide a model for the investigation
of B-ephrin reverse signaling.Acknowledgments
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